CN109852695B - 用于诊断和疗法的外来体中的miRNA生物发生 - Google Patents

用于诊断和疗法的外来体中的miRNA生物发生 Download PDF

Info

Publication number
CN109852695B
CN109852695B CN201910120129.9A CN201910120129A CN109852695B CN 109852695 B CN109852695 B CN 109852695B CN 201910120129 A CN201910120129 A CN 201910120129A CN 109852695 B CN109852695 B CN 109852695B
Authority
CN
China
Prior art keywords
mir
hsa
mmu
exosomes
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910120129.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109852695A (zh
Inventor
R·卡卢利
S·梅洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
University of Texas System
Original Assignee
Beth Israel Deaconess Medical Center Inc
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, University of Texas System filed Critical Beth Israel Deaconess Medical Center Inc
Priority to CN201910120129.9A priority Critical patent/CN109852695B/zh
Publication of CN109852695A publication Critical patent/CN109852695A/zh
Application granted granted Critical
Publication of CN109852695B publication Critical patent/CN109852695B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
CN201910120129.9A 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生 Active CN109852695B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910120129.9A CN109852695B (zh) 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361791301P 2013-03-15 2013-03-15
US61/791,301 2013-03-15
CN201910120129.9A CN109852695B (zh) 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生
CN201480022292.7A CN105264092B (zh) 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生
PCT/US2014/027541 WO2014152622A1 (en) 2013-03-15 2014-03-14 Mirna biogenesis in exosomes for diagnosis and therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480022292.7A Division CN105264092B (zh) 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生

Publications (2)

Publication Number Publication Date
CN109852695A CN109852695A (zh) 2019-06-07
CN109852695B true CN109852695B (zh) 2023-11-21

Family

ID=51581257

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910120129.9A Active CN109852695B (zh) 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生
CN201480022292.7A Active CN105264092B (zh) 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480022292.7A Active CN105264092B (zh) 2013-03-15 2014-03-14 用于诊断和疗法的外来体中的miRNA生物发生

Country Status (15)

Country Link
US (2) US20160024503A1 (enExample)
EP (2) EP2971162B1 (enExample)
JP (2) JP6554458B2 (enExample)
KR (1) KR102183406B1 (enExample)
CN (2) CN109852695B (enExample)
AU (2) AU2014239309B2 (enExample)
BR (1) BR112015023275B1 (enExample)
CA (2) CA2905081C (enExample)
ES (1) ES2966571T3 (enExample)
HK (1) HK1218143A1 (enExample)
IL (2) IL241409B (enExample)
MX (2) MX373957B (enExample)
PT (1) PT3527670T (enExample)
RU (2) RU2018101152A (enExample)
WO (1) WO2014152622A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016150475A1 (en) * 2015-03-22 2016-09-29 Universite De Liege Circulating micrornas for the diagnosis of breast cancer
CN104774966B (zh) * 2015-05-01 2017-07-28 北京博奥医学检验所有限公司 肺腺癌miRNA标记物
CA2988585A1 (en) 2015-06-10 2016-12-15 Raghu Kalluri Use of exosomes for the treatment of disease
CN107151661A (zh) * 2016-03-02 2017-09-12 上海润腾生物科技有限公司 一种人外泌体蛋白、试剂盒及其应用
CN106202984B (zh) * 2016-08-26 2018-09-04 赵毅 一种基于多层复杂网络对肿瘤miRNA标志物的筛选方法
WO2018071806A1 (en) * 2016-10-13 2018-04-19 University Of Louisville Research Foundation, Inc. Exosomal biomarkers for diagnosis and prognosis of cancer and related methods
CN110024037B (zh) 2016-11-30 2023-06-27 微软技术许可有限责任公司 经由连接的dna随机存取存储系统
US10793897B2 (en) * 2017-02-08 2020-10-06 Microsoft Technology Licensing, Llc Primer and payload design for retrieval of stored polynucleotides
US11377699B2 (en) * 2017-11-30 2022-07-05 Provincial Health Services Authority Methods for evaluating head and neck cancers
JP7474702B2 (ja) 2018-03-28 2024-04-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
KR20210005031A (ko) 2018-03-29 2021-01-13 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. Pten 억제제를 포함하는 소포 및 이의 용도
TWI805739B (zh) * 2018-04-17 2023-06-21 臺北榮民總醫院 阻斷緊迫導致腫瘤生成之方法
JP7462227B2 (ja) * 2018-04-25 2024-04-05 東レ株式会社 膀胱がんの検出のためのキット、デバイス及び方法
US12339205B2 (en) 2018-10-17 2025-06-24 H.U. Group Research Institute G. K. Method for recovering extracellular vesicles
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
AU2020217747B2 (en) 2019-02-08 2025-01-02 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
WO2020163553A1 (en) * 2019-02-08 2020-08-13 Virginia Commonwealth University Mda-7/il-24 for cancer treatment and methods of monitoring same
CN118512468A (zh) * 2019-02-26 2024-08-20 首尔大学校产学协力团 包含末端尿苷酰基转移酶4/7表达调控因子的用于预防或治疗癌症的药学组合物
MX2022000074A (es) * 2019-07-02 2022-04-06 Ohio State Innovation Foundation Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro.
US20220275455A1 (en) * 2019-07-08 2022-09-01 Preferred Networks, Inc. Data processing and classification for determining a likelihood score for breast disease
CN110358835A (zh) * 2019-07-26 2019-10-22 泗水县人民医院 生物标志物在胃癌检测、诊断中的应用
KR102212699B1 (ko) * 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
CN110607361A (zh) * 2019-10-08 2019-12-24 南京市儿童医院 miR-431作为靶点在制备促进SP表达的药物中的应用
EP4067472A4 (en) 2019-12-23 2023-12-27 Fujirebio Inc. METHOD FOR OBTAINING EXTRACELLULAR VESICLES AND BLOOD COLLECTION TUBE
EP3862442A3 (en) * 2020-02-04 2021-10-27 Artemisia S.p.A. Method for the early diagnosis of cancer by means of ddpcr analysis of mirna in liquid biopsy
EP3862441A3 (en) * 2020-02-04 2021-10-27 Artemisia S.p.A. Method for the early diagnosis of cancer by means of ddpcr analysis of mirna and protein markers in liquid biopsy
KR102318328B1 (ko) * 2020-04-13 2021-10-27 고려대학교 산학협력단 Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물
US20230227916A1 (en) 2020-04-15 2023-07-20 H.U. Group Research Institute G.K. Method for recovering extracellular vesicle
CN111920961B (zh) * 2020-08-14 2023-09-08 福建医科大学附属协和医院 一种治疗癌症的药物
JP7662161B2 (ja) * 2020-09-08 2025-04-15 ウロテック． カンパニー リミテッド 前立腺癌診断スコアを算出するための方法及びそれの使用
KR102497196B1 (ko) 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
JP7460203B2 (ja) * 2020-11-11 2024-04-02 国立研究開発法人物質・材料研究機構 細胞で産生された膜小胞に由来する塩基配列を解析する方法、その装置、及び、そのプログラム
CN112662752B (zh) * 2021-01-18 2022-08-23 中国农业大学 一种诊断用生物标志物的应用
CN112760381B (zh) * 2021-02-08 2022-11-01 复旦大学附属中山医院 一种检测肺腺癌预后的miRNA试剂盒
KR102310302B1 (ko) * 2021-02-08 2021-10-06 을지대학교 산학협력단 엑소좀 기반 방광암 진단을 위한 정보 제공 방법
CN117802235B (zh) * 2022-09-30 2025-08-19 上海思路迪生物医学科技有限公司 血液胞外囊泡miRNA在卵巢癌诊断中的应用
CN116121377A (zh) * 2022-11-01 2023-05-16 山西医科大学 一种食管鳞癌外泌体富含的miRNA作为诊断食管鳞癌的标志物中的应用
CN117778574B (zh) * 2023-12-25 2024-09-03 山东中医药大学 Mir937基因组拷贝数扩增在卵巢癌诊断和/或治疗中的应用
CN118421798B (zh) * 2024-05-22 2025-02-07 南通市海门区人民医院 用于检测结直肠癌相关血清生物标志物、sers传感器及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616476A (zh) * 2004-09-16 2005-05-18 浙江大学 针对表皮生长因子基因的小干扰核糖核酸分子及其用途
CN101755208A (zh) * 2007-07-25 2010-06-23 路易斯维尔大学研究基金会公司 作为诊断标记物的外来体相关微rna
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
WO2013022995A2 (en) * 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064949A1 (en) 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US8455199B2 (en) * 2007-09-14 2013-06-04 The Ohio State University Research Foundation MicroRNA expression in human peripheral blood microvesicles and uses thereof
EP2197497B1 (en) * 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
EP2604704B1 (en) 2008-02-01 2018-10-03 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of brain tumor
WO2009108860A2 (en) * 2008-02-28 2009-09-03 The Ohio University Rasearch Foundation Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
US20110172295A1 (en) * 2008-04-11 2011-07-14 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING
EP2294196A1 (en) 2008-06-06 2011-03-16 Centre National de la Recherche Scientifique - CNRS Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
CA2795776A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US10081542B2 (en) * 2010-04-20 2018-09-25 University of Florida Research Foundation, lnc. Nanozymes, methods of making nanozymes, and methods of using nanozymes
CN109432126B (zh) * 2011-03-11 2022-06-14 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物
EP2699271A4 (en) * 2011-04-20 2015-10-07 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY
US9777042B2 (en) 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
DK3076949T3 (da) 2013-12-04 2019-11-25 Univ Texas Fremgangsmåde til isolering af kræftcelle-afledte eksosomer
HUE059718T2 (hu) * 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616476A (zh) * 2004-09-16 2005-05-18 浙江大学 针对表皮生长因子基因的小干扰核糖核酸分子及其用途
CN101755208A (zh) * 2007-07-25 2010-06-23 路易斯维尔大学研究基金会公司 作为诊断标记物的外来体相关微rna
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
WO2013022995A2 (en) * 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma;Tatsuaki Tagami等;《DRUG DELIVERY AND TRANSLATIONAL RESEARCH》;20110409;第1卷(第4期);第277-288页 *
Argonaute亚族蛋白对人类肿瘤细胞周期的影响;姜琳等;《生物化学与生物物理进展》;20081205;第35卷(第12期);第1394-1402页 *
Dicer基因抑制对卵巢癌侵袭性及耐药性影响的实验研究;况燕;《中国优秀博硕士学位论文全文数据库(博士) 医药卫生科技辑》;20120815;第E072-41页 *
Horizontal Transfer of RNAs: Exosomes as mediators of intercellular communication;Saraswathi Ramachandran等;《Wiley Interdiscip Rev RNA》;20111019;第3卷(第2期);第286-293页 *
Richard I. Gregory等.Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing.2005,第123卷(第4期),第631-640页. *
Small Interfering RNAs against the TAR RNA Binding Protein, TRBP, a Dicer Cofactor, Inhibit Human Immunodeficiency Virus Type 1 Long Terminal Repeat Expression and Viral Production;Helen S. Christensen等;《J Virol》;20070314;第81卷(第10期);第5121-5131页 *

Also Published As

Publication number Publication date
AU2020203590A1 (en) 2020-06-18
EP3527670B1 (en) 2023-10-18
AU2020203590B2 (en) 2023-06-22
US20200255831A1 (en) 2020-08-13
CA3209023A1 (en) 2014-09-25
CN105264092B (zh) 2019-02-22
CN105264092A (zh) 2016-01-20
JP6807351B2 (ja) 2021-01-06
KR20160006673A (ko) 2016-01-19
RU2644247C2 (ru) 2018-02-08
AU2014239309A1 (en) 2015-10-08
US20160024503A1 (en) 2016-01-28
MX373957B (es) 2020-07-13
EP2971162A4 (en) 2016-11-16
BR112015023275A2 (pt) 2017-07-18
PT3527670T (pt) 2024-01-18
IL241409A0 (en) 2015-11-30
BR112015023275A8 (pt) 2018-01-23
BR112015023275B1 (pt) 2022-06-21
JP6554458B2 (ja) 2019-07-31
EP3527670A1 (en) 2019-08-21
RU2018101152A3 (enExample) 2019-02-21
EP2971162B1 (en) 2019-05-08
WO2014152622A1 (en) 2014-09-25
KR102183406B1 (ko) 2020-12-11
EP2971162A1 (en) 2016-01-20
CN109852695A (zh) 2019-06-07
IL273829A (en) 2020-05-31
RU2015144212A (ru) 2017-04-21
AU2014239309B2 (en) 2020-03-05
IL241409B (en) 2020-04-30
RU2018101152A (ru) 2019-02-21
JP2016520803A (ja) 2016-07-14
US11926824B2 (en) 2024-03-12
MX2020005165A (es) 2020-08-20
CA2905081C (en) 2023-10-03
CA2905081A1 (en) 2014-09-25
JP2018138057A (ja) 2018-09-06
ES2966571T3 (es) 2024-04-23
MX2015013141A (es) 2016-06-21
IL273829B (en) 2021-12-01
HK1218143A1 (zh) 2017-02-03

Similar Documents

Publication Publication Date Title
AU2020203590B2 (en) Mirna biogenesis in exosomes for diagnosis and therapy
Wang et al. Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by targeting MTMR3 and activating the NF-κB signaling pathway
Vashisht et al. Using miRNAs as diagnostic biomarkers for male infertility: Opportunities and challenges
Zhang et al. Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma
US9315809B2 (en) Differentially expressed microRNA molecules for the treatment and diagnosis of cancer
CN103648505B (zh) 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
Menachem et al. Intercellular transfer of small RNAs from astrocytes to lung tumor cells induces resistance to chemotherapy
Deng et al. Exosomal miR-145-5p promotes apoptosis of renal tubule epithelial cells through the JNK signalling pathway
Kumari Understanding the Internalization of Follicular Fluid Extracellular MiRNAs in Buffalo Granulosa Cells
Liu MicroRNA regulation of prostate cancer stem/progenitor cells and prostate cancer development
Papadopoulos miRNAs in kidney disease
INCHE ZAINAL ABIDIN Role of MicroRNAs in determining the cancer-associated fibroblast phenotype
Blelloch MicroRNAs to Pathways in Prostate Cancer Progression
Arduino Salivary extracellular vesicles microRNAs profiling as suitable non-invasive source for biomarkers in oral cancer
Gordanpour MicroRNAs as Prognostic Biomarkers in Prostate Cancer
Rice Mediating Prostate Cancer Metastasis Through the MicroRNA Cluster MiR-23b/-27b
Shah The Contribution of Cancer Associated Fibroblasts in Breast Cancer Progression
Yang Molecular and Functional Characterization of MicroRNA-137 in Oligodendroglial Tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant